Ceramide Signaling and Metabolism in Pathophysiological States of the Lung

Annual Review of Physiology

Volumn 78, Issue , 2016, Pages 463-480

  Petrache, Irina ^a   Berdyshev, Evgeny V ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Airways; Apoptosis; Inflammation; Metabolomics; Pulmonary; Sphingolipids

Indexed keywords

CERAMIDE; LYSOPHOSPHOLIPID; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANALOGS AND DERIVATIVES; ANIMAL; HUMAN; LUNG; LUNG DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CERAMIDES; HUMANS; LUNG; LUNG DISEASES; LYSOPHOSPHOLIPIDS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84958613659     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021115-105221     Document Type: Review

References (114)

1. Zhao Y, Kalari SK, Usatyuk PV, Gorshkova I, He D, et al. 2007. Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1. J. Biol. Chem. 282:14165-77
2. Petrache I, Kamocki K, PoirierC,Pewzner-JungY,Laviad EL, et al. 2013. Ceramide synthases expression and role of ceramide synthase-2 in the lung: insight from human lung cells and mouse models. PLOS ONE 8:e62968
3. Xu Z, Zhou J, McCoyDM, Mallampalli RK. 2005. LASS5 is the predominant ceramide synthase isoform involved in de novo sphingolipid synthesis in lung epithelia. J. Lipid Res. 46:1229-38
4. Poirier C, Berdyshev EV, Dimitropoulou C, Bogatcheva NV, Biddinger PW, Verin AD. 2012. Neutral sphingomyelinase 2 deficiency is associated with lung anomalies similar to emphysema. Mamm. Genome 23:758-63
5. Longo CA, Tyler D, Mallampalli RK. 1997. Sphingomyelin metabolism is developmentally regulated in rat lung. Am. J. Respir. Cell Mol. Biol. 16:605-12
6. Spiegel S, Milstien S. 2011. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11:403-15
7. Rosen H, Goetzl EJ. 2005. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5:560-70
8. Justice MJ, Petrusca DN, Rogozea AL, Williams JA, Schweitzer KS, et al. 2014. Effects of lipid interactions on model vesicle engulfment by alveolar macrophages. Biophys. J. 106:598-609
9. Pinto SN, Laviad EL, Stiban J, Kelly SL, Merrill AH Jr, et al. 2014. Changes in membrane biophysical properties induced by sphingomyelinase depend on the sphingolipid N-acyl chain. J. Lipid Res. 55:53-61
10. Hannun YA, Obeid LM. 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9:139-50
11. Peng H, Li C, Kadow S, Henry BD, Steinmann J, et al. 2015. Acid sphingomyelinase inhibition protects mice from lung edema and lethal Staphylococcus aureus sepsis. J. Mol. Med. 93:675-89
12. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, et al. 1997. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J. Exp. Med. 186:1831-41
13. Goggel R,Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, et al. 2004. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat. Med. 10:155-60
14. Tibboel J,Reiss I, de Jongste JC, Post M. 2014. Sphingolipids in lung growth and repair. Chest 145:120-28
15. Devlin CM, Lahm T, Hubbard WC, Van Demark M, Wang KC, et al. 2011. Dihydroceramide-based response to hypoxia. J. Biol. Chem. 286:38069-78
16. KueblerWM, Yang Y, Samapati R, Uhlig S. 2010. Vascular barrier regulation by PAF, ceramide, caveolae, and NO-an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature. Cell. Physiol. Biochem. 26:29-40
17. Samapati R, Yang Y, Yin J, Stoerger C, Arenz C, et al. 2012. Lung endothelial Ca2+ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6. Am. J. Respir. Crit. Care Med. 185:160-70
18. Presson RG Jr, Brown MB, Fisher AJ, Sandoval RM, Dunn KW, et al. 2011. Two-photon imaging within the murine thorax without respiratory and cardiac motion artifact. Am. J. Pathol. 179:75-82
19. Natarajan V, Dudek SM, Jacobson JR, Moreno-Vinasco L, Huang LS, et al. 2013. Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury. Am. J. Respir. Cell Mol. Biol. 49:6-17
20. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, et al. 2011. Endotheliumprotective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. PNAS 108:9613-18
21. Szczepaniak WS, Zhang Y, Hagerty S, Crow MT, Kesari P, et al. 2008. Sphingosine 1-phosphate rescues canine LPS-induced acute lung injury and alters systemic inflammatory cytokine production in vivo. Transl. Res. 152:213-24
22. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, et al. 2001. Sphingosine 1-phosphate promotes endothelial cell barrier integrity byEdg-dependent cytoskeletal rearrangement. J. Clin. Investig. 108:689-701
23. Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, et al. 2004. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J. Biol. Chem. 279:24692-700
24. Shikata Y, Birukov KG, Garcia JG. 2003. S1P induces FA remodeling in human pulmonary endothelial cells: role of Rac, GIT1, FAK, and paxillin. J. Appl. Physiol. 94:1193-203
25. Bhattacharya M, Su G, Su X, Oses-Prieto JA, Li JT, et al. 2012. IQGAP1 is necessary for pulmonary vascular barrier protection in murine acute lung injury and pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 303:L12-19
26. Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, et al. 2010. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am. J. Respir. Cell Mol. Biol. 43:394-402
27. Sun X, Singleton PA, Letsiou E, Zhao J, Belvitch P, et al. 2012. Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury. Am. J. Respir. Cell Mol. Biol. 47:628-36
28. Sun X, Ma SF, Wade MS, Acosta-Herrera M, Villar J, et al. 2013. Functional promoter variants in sphingosine 1-phosphate receptor 3 associate with susceptibility to sepsis-associated acute respiratory distress syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 305:L467-77
29. StraderCR, Pearce CJ,Oberlies NH. 2011. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J. Nat. Prod. 74:900-7
30. Lu X, Byun HS, Bittman R. 2004. Synthesis of l-lyxo-phytosphingosine and its 1-phosphonate analogue using a threitol acetal synthon. J. Org. Chem. 69:5433-38
31. Lu X, Sun C, Valentine WJ, Shuyu E, Liu J, et al. 2009. Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720. J. Org. Chem. 74:3192-95
32. Camp SM, Bittman R, Chiang ET, Moreno-Vinasco L, Mirzapoiazova T, et al. 2009. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J. Pharmacol. Exp. Ther. 331:54-64
33. Wang L, Sammani S, Moreno-Vinasco L, Letsiou E, Wang T, et al. 2014. FTY720 (S)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury. Crit. Care Med. 42:e189-99
34. Zhao Y, Gorshkova IA, Berdyshev E, He D, Fu P, et al. 2011. Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am. J. Respir. Cell Mol. Biol. 45:426-35
35. Jozefowski S, Czerkies M, Lukasik A, Bielawska A, Bielawski J, et al. 2010. Ceramide and ceramide 1-phosphate are negative regulators of TNF-αproduction induced by lipopolysaccharide. J. Immunol. 185:6960-73
36. von Bismarck P,Winoto-Morbach S, Herzberg M, Uhlig U, Schutze S, et al. 2012. IKK NBD peptide inhibits LPS induced pulmonary inflammation and alters sphingolipid metabolism in a murine model. Pulm. Pharmacol. Ther. 25:228-35
37. Chang ZQ, Lee SY, Kim HJ, Kim JR, Kim SJ, et al. 2011. Endotoxin activates de novo sphingolipid biosynthesis via nuclear factor kappa B-mediated upregulation of Sptlc2. Prostaglandins Other Lipid Mediat. 94:44-52
38. Monick MM, Mallampalli RK, Bradford M, McCoy D, Gross TJ, et al. 2004. Cooperative prosurvival activity by ERK and Akt in human alveolar macrophages is dependent on high levels of acid ceramidase activity. J. Immunol. 173:123-35
39. LinWC, LinCF, Chen CL,ChenCW, Lin YS. 2011. Inhibition of neutrophil apoptosis via sphingolipid signaling in acute lung injury. J. Pharmacol. Exp. Ther. 339:45-53
40. AliM, Saroha A, Pewzner-Jung Y, Futerman AH. 2015. LPS-mediated septic shock is augmented in ceramide synthase 2 null mice due to elevated activity of TNFα-converting enzyme. FEBS Lett. 589:2213-17
41. Hou J, Chen Q, Zhang K, Cheng B, Xie G, et al. 2015. Sphingosine 1-phosphate receptor 2 signaling suppresses macrophage phagocytosis and impairs host defense against sepsis. Anesthesiology 123:409-22
42. Baudiss K, Ayata CK, Lazar Z, Cicko S, Beckert J, et al. 2015. Ceramide-1-phosphate inhibits cigarette smoke-induced airway inflammation. Eur. Respir. J. 45:1669-80
43. Lamour NF, Chalfant CE. 2005. Ceramide-1-phosphate: the "missing" link in eicosanoid biosynthesis and inflammation. Mol. Interv. 5:358-67
44. Rivera IG, Ordonez M, PresaN,Gomez-Larrauri A, Simon J, et al. 2015. Sphingomyelinase D/ceramide 1-phosphate in cell survival and inflammation. Toxins 7:1457-66
45. Arana L, Gangoiti P, Ouro A, TruebaM, Gomez-Munoz A. 2010. Ceramide and ceramide 1-phosphate in health and disease. Lipids Health Dis. 9:15
46. Cornell TT, Hinkovska-Galcheva V, Sun L, Cai Q, Hershenson MB, et al. 2009. Ceramide-dependent PP2A regulation of TNFα-induced IL-8 production in respiratory epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 296:L849-56
47. Ryan AJ, McCoy DM, McGowan SE, Salome RG, Mallampalli RK. 2003. Alveolar sphingolipids generated in response to TNF-αmodifies surfactant biophysical activity. J. Appl. Physiol. 1985 94:253-58
48. von Bismarck P,Wistadt CF, Klemm K, Winoto-Morbach S, Uhlig U, et al. 2008. Improved pulmonary function by acid sphingomyelinase inhibition in a newborn piglet lavage model. Am. J. Respir. Crit. Care Med. 177:1233-41
49. Tabeling C, Yu H,Wang L, Ranke H, Goldenberg NM, et al. 2015. CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction. PNAS 112:E1614-23
50. Garg SK, Volpe E, Palmieri G, Mattei M, Galati D, et al. 2004. Sphingosine 1-phosphate induces antimicrobial activity both in vitro and in vivo. J. Infect. Dis. 189:2129-38
51. Pewzner-Jung Y, Tavakoli Tabazavareh S, Grassme H, Becker KA, Japtok L, et al. 2014. Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa. EMBO Mol. Med. 6:1205-14
52. Bhat S, Spitalnik SL, Gonzalez-Scarano F, Silberberg DH. 1991. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. PNAS 88:7131-34
53. Finnegan CM, Rawat SS, Puri A, Wang JM, Ruscetti FW, Blumenthal R. 2004. Ceramide, a target for antiretroviral therapy. PNAS 101:15452-57
54. Monick MM, Cameron K, Powers LS, Butler NS, McCoy D, et al. 2004. Sphingosine kinase mediates activation of extracellular signal-related kinase and Akt by respiratory syncytial virus. Am. J. Respir. Cell Mol. Biol. 30:844-52
55. Pritzl CJ, Seo YJ, XiaC, Vijayan M, Stokes ZD, Hahm B. 2015. A ceramide analogue stimulates dendritic cells to promote T cell responses upon virus infections. J. Immunol. 194:4339-49
56. Kawakami K, Kinjo Y, Yara S, Koguchi Y, Uezu K, et al. 2001. Activation of Vα14+ natural killer T cells by α-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69:213-20
57. Tuder RM, Petrache I. 2012. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Investig. 122:2749-55
58. Petrache I, Petrusca DN. 2013. The involvement of sphingolipids in chronic obstructive pulmonary diseases. Handb. Exp. Pharmacol. 2013:247-64
59. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, et al. 2005. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat. Med. 11:491-98
60. Petrusca DN, Gu Y, Adamowicz JJ, Rush NI, Hubbard WC, et al. 2010. Sphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages. J. Biol. Chem. 285:40322-32
61. Korns D, Frasch SC, Fernandez-Boyanapalli R, Henson PM, Bratton DL. 2011. Modulation of macrophage efferocytosis in inflammation. Front. Immunol. 2:57
62. BodasM,Min T, Vij N. 2015. Lactosylceramide-accumulation in lipid-rafts mediate aberrant-autophagy, inflammation and apoptosis in cigarette smoke induced emphysema. Apoptosis 20:725-39
63. Diab KJ, Adamowicz JJ, Kamocki K, Rush NI, Garrison J, et al. 2010. Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema. Am. J. Respir. Crit. Care Med. 181:344-52
64. Christofidou-Solomidou M, Pietrofesa RA, Arguiri E, Schweitzer KS, Berdyshev EV, et al. 2015. Space radiation associated lung injury in a murine model. Am. J. Physiol. Lung Cell. Mol. Physiol. 308:L416-28
65. Bowler RP, Jacobson S, Cruickshank C,Hughes GJ, Siska C, et al. 2015. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am. J. Respir. Crit. Care Med. 191:275-84
66. Cruickshank-Quinn CI, Mahaffey S, Justice MJ, Hughes G, Armstrong M, et al. 2014. Transient and persistent metabolomic changes in plasma following chronic cigarette smoke exposure in a mousemodel. PLOS ONE 9:e101855
67. Petrache I, Medler TR, Richter AT, Kamocki K, Chukwueke U, et al. 2008. Superoxide dismutase protects against apoptosis and alveolar enlargement induced by ceramide. Am. J. Physiol. Lung Cell. Mol. Physiol. 295:L44-53
68. Grassme H, Riethmuller J, Gulbins E. 2013. Ceramide in cystic fibrosis. Handb. Exp. Pharmacol. 2013:265-74
69. Brodlie M, Lordan JL, Ward C. 2011. Ceramide and cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 183:133
70. Becker KA, Henry B, Ziobro R, Riethmuller J, Gulbins E. 2011. Lipids in cystic fibrosis. Expert Rev. Respir. Med. 5:527-35
71. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, et al. 2008. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14:382-91
72. Becker KA, Grassme H, Zhang Y, Gulbins E. 2010. Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis. Cell. Physiol. Biochem. 26:57-66
73. Boujaoude LC, Bradshaw-Wilder C, Mao C, Cohn J, Ogretmen B, et al. 2001. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J. Biol. Chem. 276:35258-64
74. Hamai H, Keyserman F, Quittell LM,Worgall TS. 2009. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J. Lipid Res. 50:1101-8
75. Noe J, Petrusca D, Rush N, Deng P, VanDemark M, et al. 2009. CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis. Am. J. Respir. Cell Mol. Biol. 41:314-23
76. CantinAM, Hanrahan JW, Bilodeau G, Ellis L, DupuisA, et al. 2006. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers.Am. J. Respir. Crit.CareMed. 173:1139-44
77. Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, et al. 2012. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J. 26:533-45
78. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, et al. 2007. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448:470-73
79. MoffattMF, Gut IG, Demenais F, Strachan DP, Bouzigon E, et al. 2010. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363:1211-21
80. Sharma S, Zhou X, Thibault DM, Himes BE, Liu A, et al. 2014. A genome-wide survey of CD4+ lymphocyte regulatory genetic variants identifies novel asthma genes. J. Allergy Clin. Immunol. 134:1153-62
81. Oyeniran C, Sturgill JL, Hait NC, Huang WC, Avni D, et al. 2015. Aberrant ORM (yeast)-like protein isoform 3 (ORMDL3) expression dysregulates ceramide homeostasis in cells and ceramide exacerbates allergic asthma in mice. J. Allergy Clin. Immunol. 136:1035-46.e6
82. Siow D, Sunkara M, Dunn TM, Morris AJ, Wattenberg B. 2015. ORMDL/serine palmitoyltransferase stoichiometry determines effects of ORMDL3 expression on sphingolipid biosynthesis. J. Lipid Res. 56:898-908
83. Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S. 2002. The roles of sphingosine-1-phosphate in asthma. Mol. Immunol. 38:1239-45
84. Fuerst E, Foster HR, Ward JP, Corrigan CJ, Cousins DJ, Woszczek G. 2014. Sphingosine-1-phosphate induces pro-remodelling response in airway smooth muscle cells. Allergy 69:1531-39
85. Price MM, Oskeritzian CA, Falanga YT,Harikumar KB, Allegood JC, et al. 2013. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J. Allergy Clin. Immunol. 131:501-11.e1
86. Trifilieff A, Fozard JR. 2012. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor. J. Pharmacol. Exp. Ther. 342:399-406
87. Karmouty-Quintana H, Siddiqui S, Hassan M, Tsuchiya K, Risse PA, et al. 2012. Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure. Am. J. Physiol. Lung Cell. Mol. Physiol. 302:L736-45
88. Chiba Y, Takeuchi H, Sakai H, Misawa M. 2010. SKI-II, an inhibitor of sphingosine kinase, ameliorates antigen-induced bronchial smooth muscle hyperresponsiveness, but not airway inflammation, in mice. J. Pharmacol. Sci. 114:304-10
89. Roviezzo F, D'Agostino B, Brancaleone V, De Gruttola L, Bucci M, et al. 2010. Systemic administration of sphingosine-1-phosphate increases bronchial hyperresponsiveness in the mouse. Am. J. Respir. Cell Mol. Biol. 42:572-77
90. Roviezzo F, Di Lorenzo A, Bucci M, Brancaleone V, Vellecco V, et al. 2007. Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 36:757-62
91. Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, et al. 2001. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J. 15:1212-14
92. Rosenfeldt HM, Amrani Y,Watterson KR,Murthy KS, Panettieri RA Jr, Spiegel S. 2003. Sphingosine-1-phosphate stimulates contraction of human airway smooth muscle cells. FASEB J. 17:1789-99
93. Oskeritzian CA, Hait NC,Wedman P, Chumanevich A, Kolawole EM, et al. 2015. The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses. J. Allergy Clin. Immunol. 135:1008-18.e1
94. Huang LS, Berdyshev E, Mathew B, Fu P, Gorshkova IA, et al. 2013. Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. FASEB J. 27:1749-60
95. Milara J, Navarro R, Juan G, Peiro T, Serrano A, et al. 2012. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax 67:147-56
96. Huang LS, Natarajan V. 2015. Sphingolipids in pulmonary fibrosis. Adv. Biol. Regul. 57:55-63
97. Murakami K, Kohno M, Kadoya M, Nagahara H, Fujii W, et al. 2014. Knock out of S1P3 receptor signaling attenuates inflammation and fibrosis in bleomycin-induced lung injury mice model. PLOS ONE 9:e106792
98. Sobel K,Menyhart K, KillerN, Renault B, Bauer Y, et al. 2013. Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling. J. Biol. Chem. 288:14839-51
99. Gorshkova I, Zhou T,Mathew B, Jacobson JR, Takekoshi D, et al. 2012. Inhibition of serine palmitoyltransferase delays the onset of radiation-induced pulmonary fibrosis through the negative regulation of sphingosine kinase-1 expression. J. Lipid Res. 53:1553-68
100. Mathew B, Jacobson JR, Berdyshev E, Huang Y, Sun X, et al. 2011. Role of sphingolipids in murine radiation-induced lung injury: protection by sphingosine 1-phosphate analogs. FASEB J. 25:3388-400
101. RobertsWC, Fredrickson DS. 1967. Gaucher's disease of the lung causing severe pulmonary hypertension with associated acute recurrent pericarditis. Circulation 35:783-89
102. Petrusca DN, Van Demark M, Gu Y, Justice MJ, Rogozea A, et al. 2014. Smoking exposure induces human lung endothelial cell adaptation to apoptotic stress. Am. J. Respir. Cell Mol. Biol. 50:513-25
103. Chen J, Tang H, Sysol JR, Moreno-Vinasco L, Shioura KM, et al. 2014. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 190:1032-43
104. Hsiao SH, Constable PD, Smith GW, Haschek WM. 2005. Effects of exogenous sphinganine, sphingosine, and sphingosine-1-phosphate on relaxation and contraction of porcine thoracic aortic and pulmonary arterial rings. Toxicol. Sci. 86:194-99
105. Ota H, Beutz MA, Ito M, Abe K, Oka M, McMurtry IF. 2011. S1P4 receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Pulm. Circ. 1:399-404
106. Haberberger RV, Tabeling C, Runciman S, Gutbier B, Konig P, et al. 2009. Role of sphingosine kinase 1 in allergen-induced pulmonary vascular remodeling and hyperresponsiveness. J. Allergy Clin. Immunol. 124:933-41.e1-9
107. Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, et al. 2001. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J. Biol. Chem. 276:24901-10
108. ChalfantCE, RathmanK, Pinkerman RL,Wood RE,Obeid LM, et al. 2002. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells: dependence on protein phosphatase-1. J. Biol. Chem. 277:12587-95
109. Alberg AJ, Armeson K, Pierce JS, Bielawski J, Bielawska A, et al. 2013. Plasma sphingolipids and lung cancer: a population-based, nested case-control study. Cancer Epidemiol. Biomark. Prev. 22:1374-82
110. Lam CW, Law CY. 2014. Untargeted mass spectrometry-based metabolomic profiling of pleural effusions: fatty acids as novel cancer biomarkers for malignant pleural effusions. J. Proteome Res. 13:4040-46
111. Kabayama K, Ito N, Honke K, Igarashi Y, Inokuchi J. 2001. Suppression of integrin expression and tumorigenicity by sulfation of lactosylceramide in 3LL Lewis lung carcinoma cells. J. Biol. Chem. 276:26777-83
112. Tyler A, Johansson A, Karlsson T, Gudey SK, Brannstrom T, et al. 2015. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. Exp. Cell Res. 336:23-32
113. Yazama H, Kitatani K, Fujiwara K, Kato M, Hashimoto-Nishimura M, et al. 2015. Dietary glucosylceramides suppress tumor growth in a mouse xenograft model of head and neck squamous cell carcinoma by the inhibition of angiogenesis through an increase in ceramide. Int. J. Clin. Oncol. 20:438-46
114. Tibboel J, Reiss I, de Jongste JC, Post M. 2013. Ceramides: a potential therapeutic target in pulmonary emphysema. Respir. Res. 14:96